Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRT regimen versus standard cyclophosphamide-based therapy for anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease
jRCT2061260009Phase 2Recruiting
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of baricitinib, rituximab, cyclophosphamide, tacrolimus, methylprednisolone and 1 more in dermatomyositis (DM), interstitial lung disease (ILD) and dermatomyositis-associated interstitial lung disease (DM-ILD) (2 arms), sponsored by Nippon Zenyaku Kogyo Co., Ltd. Primary endpoint: Overall survival. Started Apr 2026; status: recruiting.
02
Drugs
baricitinibrituximabcyclophosphamidetacrolimusmethylprednisolone
03
Conditions
dermatomyositis (DM)interstitial lung disease (ILD)dermatomyositis-associated interstitial lung disease (DM-ILD)
Beyond the preview
Go deeper on jRCT2061260009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260009.